Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yuhan Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Target and Period: Patients aged 18 or older
Target Conditions:
1. Lazertinib:
* Patients diagnosed with locally progressive or metastatic non-small cell lung cancer, who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
* Patients with T790M mutation positive
* Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration
2. Platinum-based Chemotherapy
* Patients who were diagnosed with locally advanced or metastatic non-small cell lung cancer, and previously received first or second-generation EGFR-TKI treatment during the baseline period
* Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
* Patients who were confirmed positive for active EGFR mutations (L858R, Exon19Del, G719X, L861Q) during the baseline period
* Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration
You may not be if
Patients with carcinoma besides NSCLC requiring treatment
Any unstable brain metastasis with symptomatic and/or requiring emergency treatment
